Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
Recruiting
18-99 years
All
Phase
2
3 participants needed
1 Location
Brief description of study
This study will assess the safety, tolerability, pharmacokinetics, and antiviral activity of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma viremia.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: HIV-1
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female, Age 18 or older, with HIV-1 infection
Updated on
01 Aug 2024.
Study ID: 843800
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
